Parameters
|
Total number (%)
|
---|
Age
| |
<60 years | 788 (58.46%) |
≥60 years | 560 (41.54%) |
Lenalidomide use
| |
No | 992 (73.59%) |
Yes | 356 (26.41%) |
Hematological toxicity
| |
No | 1260 (93.47%) |
Yes | 88 (6.53%) |
Baseline cytopenia
| |
No | 1016 (75.37%) |
Yes | 332 (24.63%) |
Number of parameters
| |
0 | 402 (29.82%) |
1 | 630 (46.74%) |
2 | 252 (18.69%) |
3 | 54 (4.01%) |
4 | 10 (0.74%) |
- Distribution of the four analyzed parameters potentially affecting PBSC collection in 1,348 newly diagnosed myeloma patients. Lenalidomide use: up to four cycles; baseline cytopenia: Hb <10 g/dl, neutrophil count <1 × 109/L, platelet count <100 × 109/L: at least one at diagnosis; hematological toxicity: grade 3 or 4 during induction therapy (CTCAE v4). PBSC, peripheral blood stem cells.